The FDA issued a second complete response letter for Replimune’s RP1 in advanced melanoma on Friday, and the fallout is immediate. CEO Sushil Patel said development “will not be viable” without timely accelerated approval and announced the company would eliminate jobs and substantially scale back U.S. manufacturing. A drug with a 34% response rate in a lethal cancer—in patients who had progressed on anti-PD-1 therapy with few remaining options—will not reach patients. Not because the medicine failed, as Patel put it, but because the regulatory system did not accept the evidentiary standard the company built its program around. The rejection matters well beyond Replimune. The industry was watching the RP1 decision as what Cantor Fitzgerald analyst Li Watsek called “a first indicator of how the FDA is going to act going forward.” The answer is unambiguous: the agency’s skepticism toward single-arm oncology trials remains firmly intact. Meanwhile, biopharma financing in Q1 2026 surged to $22.82 billion—up 74% from a year ago—and last week’s extraordinary density of catalysts continues to reshape the operating environment heading into Q2.
Top Story: FDA Issues Second CRL for Replimune’s RP1 in Advanced Melanoma
What Happened: The FDA issued a complete response letter on April 10 for Replimune’s BLA for RP1 (vusolimogene oderparepvec) in combination with nivolumab for advanced melanoma. This is the second CRL for the same application. The first was issued in July 2025. Replimune resubmitted in October 2025 with additional data and analyses, and the FDA accepted it as a complete response with a Class II review timeline. The April 10 PDUFA date came and went with another rejection.
The Data That Wasn’t Enough
The Phase 1/2 IGNYTE trial produced results that, by historical oncology standards, were clinically meaningful. RP1 in combination with nivolumab demonstrated a 34% overall response rate in patients who had progressed on anti-PD-1 therapy—a population where historical response rates to subsequent treatment are in the range of 6-7%. The drug achieved a 15% complete response rate and a 24.8-month median duration of response. Three-year survival data was favorable. The safety profile raised no concerns.
RP1 had Breakthrough Therapy Designation. Melanoma specialists wrote an open letter advocating for approval. Patient groups pleaded for access. The FDA accepted the BLA resubmission as a “complete response.” Every procedural signal pointed toward approval.
None of it changed the outcome.
The FDA’s Reasoning
The agency maintained that the IGNYTE trial is not considered an adequate and well-controlled clinical investigation providing substantial evidence of effectiveness. Two specific concerns drove the rejection:
Single-arm design: Without a randomized control arm, the FDA’s position is that the contribution of RP1 to the RP1/nivolumab combination cannot be adequately assessed. Patients received both RP1 and nivolumab, and the trial design does not allow the agency to determine how much of the observed response is attributable to RP1 versus nivolumab alone or the natural course of the disease.
Patient population heterogeneity: The enrolled population included patients with varying prior treatment histories, disease characteristics, and baseline status, which the FDA cited as limiting the interpretability of the results.
The CRL also raised questions about the confirmatory Phase 3 trial (IGNYTE-3), specifically around the contribution-of-components question for the RP1/nivolumab combination.
The Review Process Controversy
Replimune disclosed a procedural detail that adds a layer of controversy. A different review team was appointed for the resubmission, replacing the prior team that had interacted with the company throughout the original review process. The new team did not meet with Replimune during the review despite the company’s offer to do so.
Additionally, a senior member of the original review team had publicly stated that the clinical team believed the applicant had provided adequate evidence of effectiveness but that leadership disagreed. The implication—that the scientific reviewers supported approval but were overruled—is an extraordinary disclosure that raises questions about the internal decision-making process at CBER.
The CEO’s Response and What Comes Next
Patel’s statement was unusually direct for a pharma executive responding to a CRL. He said RP1 development “will not be viable” without timely accelerated approval and announced the company would “eliminate jobs, including substantially scaling back our U.S. based manufacturing operations.” He added: “A treatment desperately needed by patients will not be available. Not because the medicine failed. Because the system did.”
Replimune plans to request a Type A meeting with the FDA within 30 days. Whether any viable path to accelerated approval exists will determine RP1’s fate and Replimune’s future as a company.
The Phase 3 IGNYTE-3 trial—approximately 400 patients with overall survival as the primary endpoint—is underway. But without accelerated approval revenue, Replimune may not have the financial resources to complete it. Cantor Fitzgerald had estimated $800 million in peak annual sales if RP1 were approved. That estimate is now functionally stranded behind a regulatory barrier that two submissions have failed to clear.
The Signal for the Broader Industry
The Replimune rejection sends an unambiguous message to every company building an accelerated approval strategy around a single-arm oncology study: plan for the FDA to say no, regardless of the clinical data.
The agency under Commissioner Makary has demonstrated that strong response rates, breakthrough designation, physician advocacy, and patient urgency do not override its evidentiary standard for demonstrating drug effectiveness. Single-arm trials without randomized comparators face a structural disadvantage that clinical results alone cannot compensate for. Companies with registrational strategies that depend on single-arm data need backup plans—either randomized components within their trial designs or sufficient capital to fund confirmatory studies independently.
The Expedited IND pathway proposed in the FDA’s FY2027 budget is about Phase 1 access, not about lowering the approval bar. The approval bar, based on the RP1 precedent, appears to be going up rather than down.
Our Pro brief analyzes what two CRLs for the same drug tells you about the FDA’s posture on single-arm oncology studies under Makary, the internal review process controversy, and the implications for every company currently pursuing accelerated approval without randomized data. [Details below.]
What to Watch
The Type A meeting with the FDA will determine whether any path forward exists for RP1. If the agency indicates that only a completed randomized Phase 3 will support approval, Replimune faces a funding crisis that could force a sale, partnership, or wind-down. If the FDA offers constructive guidance on a modified pathway, there may be a narrow route to accelerated approval—but precedent from two CRLs makes optimism difficult to justify. Watch for workforce reduction details and any signals about IGNYTE-3 continuation.
Q1 2026 Financing: The Recovery Is Real
What Happened: BioWorld reported that total biopharma financing in Q1 2026 reached $22.82 billion, up 74% from $13.12 billion in Q1 2025. Combined with medtech financing of $8.54 billion, total life sciences capital deployment in Q1 exceeded $31 billion. Three cancer drug startups raised a combined $350 million in the first week of Q2 alone.
What Is Driving the Surge
The Q1 financing number reflects the convergence of several favorable dynamics. Strong M&A premiums—ranging from 34% to 140% across Q1 deals—are making late-stage biotechs attractive to public market investors who anticipate acquisition as a realistic exit path. The IPO window is reopening, with recent offerings increasingly featuring companies with Phase 2 or later clinical assets. Venture capital is flowing toward the therapeutic areas generating the most M&A activity: AI drug discovery, antibody-drug conjugates, and GLP-1 adjacent metabolic programs.
The $22.82 billion figure is well above the subdued financing levels seen from 2022 through 2025, though it remains below the $38.35 billion high of Q1 2021—the peak of the pandemic-era biotech boom. The recovery is real but measured, reflecting a market that is more selective about which companies and mechanisms attract capital.
IPO Pipeline Building
The financing environment is also supporting a nascent IPO pipeline. Avalyn Pharma has filed for an IPO to fund its inhaled pulmonary fibrosis pipeline. Kailera Therapeutics is in the IPO queue. The combination of strong M&A premiums providing valuation benchmarks, improving public market sentiment (XBI near pandemic-era highs), and increasing institutional appetite for clinical-stage biotech creates the most supportive IPO environment since 2021.
What It Means for the Rest of 2026
For company management teams and board members evaluating strategic options, the capital markets are the most receptive they have been in years. The decision between pursuing a partnership, an IPO, or positioning for M&A acquisition is more open than at any point since the post-pandemic downturn. That window may not stay open indefinitely—tariff uncertainty, potential clinical failures in high-profile programs, or macroeconomic deterioration could close it. But for now, the environment favors companies that are ready to access capital.
Our Pro brief includes a full analysis of the Q1 financing surge, what is driving capital allocation across therapeutic areas, how the IPO pipeline is building, and what the financing data signals about the sustainability of the current M&A cycle. [Details below.]
The Week That Changed Everything: A Recap
Last week was the most consequential week in biopharma this year. Here is the full scorecard:
Foundayo approved (April 1): Lilly’s oral GLP-1 cleared in 50 days under the CNPV program—the fastest NME approval since 2002. Shipping at $149 per month through LillyDirect. The oral GLP-1 war with Novo’s Wegovy pill is officially live.
Section 232 tariffs signed (April 2): 100% tariffs on imported patented pharmaceuticals. Tiered exemptions for onshoring (20%), MFN pricing (0%), allied countries (15%). Generics and biosimilars exempt. Companies are now in active negotiation mode.
Gilead’s $5B Tubulis deal (April 7): Third acquisition in six weeks, bringing total committed capital to approximately $15 billion across CAR-T (Arcellx), autoimmune (Ouro), and ADC oncology (Tubulis).
Neurocrine’s $2.9B Soleno deal (April 6): Largest acquisition in company history. Adds Vykat XR, the only approved Prader-Willi drug, generating $190 million in its first year with no competition and IP extending to the mid-2040s.
Sanofi lunsekimig mixed data (April 7): Hit in asthma and nasal polyps, missed in eczema. Respiratory path intact at $3 billion peak sales estimate. Pressure shifts to amlitelimab for the atopic dermatitis succession plan.
AbbVie Humira on TrumpRx at 86% off (April 7): The clearest example of the Section 232 tariff framework converting threats into pricing concessions. Template for every MFN deal to follow.
PhRMA CEO Ubl stepping down (April 8): The longest-serving PhRMA CEO departs as bilateral deal-making undermines the collective lobbying model.
FDA Expedited IND proposal (April 3): New pathway to accelerate Phase 1 trials using non-animal preclinical data. Framed as a competitive response to China’s faster regulatory timelines.
RP1 second CRL (April 10): Single-arm oncology trials face a higher bar. Plan for the FDA to say no.
Global pipeline contraction (Citeline): 22,940 drugs in development, down 3.9%. First decline since the 1990s. Fewer drugs but more companies and growing late-stage pipelines—quality over quantity.
Strategic Themes
1. The FDA’s Single-Arm Oncology Standard Is Not Negotiable
Two CRLs for the same drug, with the same fundamental concern cited both times, establishes a clear precedent. The FDA will not approve oncology drugs based on single-arm data when it cannot assess the contribution of individual components in a combination, regardless of breakthrough designation, physician advocacy, or clinical data quality. Companies currently pursuing accelerated approval strategies without randomized comparators should reassess their registrational plans. The evidentiary bar is not coming down. If anything, the RP1 precedent suggests it is being applied more stringently under the current FDA leadership.
2. The Financing Recovery Creates a Strategic Window
$22.82 billion in Q1 biopharma financing—up 74% year-over-year—is the strongest capital deployment since the pandemic boom. The combination of elevated M&A premiums, improving public market sentiment, and reopening IPO activity creates the most favorable capital access environment in years. For companies with clinical-stage assets in high-demand therapeutic areas, the window is open now. History suggests these windows do not stay open indefinitely.
3. Last Week’s Convergence Reshaped the Q2 Operating Environment
No single week in recent memory has simultaneously reshaped the competitive landscape (Foundayo), trade policy (Section 232), industry structure ($8 billion in M&A), regulatory direction (Expedited IND), institutional leadership (PhRMA CEO departure), and approval standards (RP1 CRL) at the same density. Companies that process these events individually will miss the systemic implications of their simultaneous arrival. The operating environment that existed at the start of April is fundamentally different from the one that exists now.
4. The Gap Between Clinical Significance and Regulatory Acceptance Is Widening
RP1’s 34% response rate in post-PD-1 melanoma is clinically meaningful by any measure. Physicians and patients wanted access to the drug. The FDA said no—twice. The growing disconnect between what clinicians consider evidence of effectiveness and what the agency will accept for accelerated approval creates a tension that has no easy resolution. For companies, the implication is pragmatic: design trials to the FDA’s evidentiary standard, not to the clinical community’s threshold for what constitutes a meaningful treatment advance.
Frequently Asked Questions
Why did the FDA reject RP1 a second time?
The FDA maintained that the single-arm IGNYTE trial is not adequate evidence of effectiveness because without a randomized control, the contribution of RP1 to the RP1/nivolumab combination cannot be assessed. Patient population heterogeneity was cited as a secondary concern. These were the same issues raised in the first CRL in July 2025 and were not resolved in the resubmission.
What was the RP1 clinical data?
The IGNYTE trial showed a 34% overall response rate (versus 6-7% historical rates for anti-PD-1 retreatment), a 15% complete response rate, and a 24.8-month median duration of response in patients who had progressed on anti-PD-1 therapy. The safety profile raised no concerns. The drug had Breakthrough Therapy Designation.
What happens to Replimune now?
The company plans to request a Type A meeting with the FDA within 30 days. CEO Sushil Patel said RP1 development “will not be viable” without timely accelerated approval and announced job eliminations and a substantial scaling back of U.S. manufacturing. The Phase 3 IGNYTE-3 trial (approximately 400 patients, overall survival endpoint) is underway, but Replimune may lack the resources to complete it without approval revenue.
Why was a different FDA review team assigned?
Replimune disclosed that a different review team was appointed for the resubmission, replacing the prior team that had interacted with the company throughout the original process. The new team did not meet with Replimune during the review. A senior member of the original team had publicly stated that the clinical reviewers believed the evidence was adequate but leadership disagreed.
What does this rejection mean for other oncology companies?
It signals that the FDA’s bar for single-arm accelerated approval in oncology remains high and is being applied stringently. Companies building registrational strategies around single-arm studies without randomized comparators should expect the FDA to reject them, regardless of response rates, breakthrough designation, or physician advocacy. Randomized data or a clear contribution-of-components design is effectively required.
How much did biopharma raise in Q1 2026?
$22.82 billion, up 74% from $13.12 billion in Q1 2025, according to BioWorld. Combined with $8.54 billion in medtech financing, total life sciences capital deployment exceeded $31 billion. The figure is well above 2022-2025 levels but below the $38.35 billion Q1 2021 pandemic peak.
What is driving the financing surge?
Strong M&A premiums (34% to 140% in Q1 deals) are making late-stage biotechs attractive to investors. The IPO window is reopening with companies featuring Phase 2 or later assets. VC is concentrating in AI drug discovery, ADCs, and GLP-1 adjacent programs. The overall sentiment environment (XBI near pandemic-era highs) supports capital deployment.
What should investors watch this week?
Foundayo enters its second full week of commercial availability—early prescription volume data will be the first competitive signal against Novo’s oral Wegovy. Replimune’s Type A meeting request with the FDA will determine whether any path forward exists for RP1. Companies continue negotiating MFN and onshoring agreements ahead of the July 31 Section 232 tariff deadline. Heart Rhythm 2026 kicks off later this month with major medtech presentations from Medtronic, Boston Scientific, and Abbott.
BioMed Nexus Pro — What Institutional Subscribers Are Reading Today
The RP1 Signal: What Two CRLs Mean for Single-Arm Oncology. We analyze what the Replimune rejection tells you about the FDA’s posture under Makary, the internal review process controversy, the contribution-of-components question, and the implications for every company currently pursuing accelerated approval without randomized data. If you are building a registrational strategy in oncology, this is the analysis that should inform your trial design.
Q1 Financing Surge: Recovery or Window? We break down the $22.82 billion quarter by therapeutic area, stage, and capital type, assess how M&A premiums are driving public market sentiment, and model whether the financing window stays open through Q2 or contracts on tariff uncertainty.
Last Week’s Convergence — The Full Framework. Foundayo, Section 232, $8B in M&A, a PhRMA vacuum, the Expedited IND, a pipeline contraction, and now RP1. We map all ten events into a single framework for how the operating environment has shifted and what it means for portfolio positioning across metabolic, oncology, immunology, and medtech heading into Q2.
Plus: Foundayo Week 2 monitoring, Replimune Type A meeting timeline, Heart Rhythm 2026 preview, and the updated catalyst calendar through H2 2026.
About BioMed Nexus
BioMed Nexus delivers institutional-grade intelligence to biotech and pharma executives, investors, and clinicians. Our daily briefings and deep-dive analyses cut through the noise to deliver the strategic insights that drive better decision-making in the life sciences.
Subscribe to receive daily updates and gain access to BioMed Nexus Pro institutional intelligence briefs.
